#1 Clinical Trials Search in Europe

Pneumococcal Polysaccharide Serotype 2

This article summarizes clinical trials investigating the use of pneumococcal polysaccharide serotype 2 vaccine. These trials aim to evaluate the safety, tolerability, and immune responses generated by various pneumococcal vaccine formulations containing serotype 2, often in combination with other serotypes. The studies involve different patient populations, including healthy adults, children, and those at increased risk of pneumococcal disease.

Table of Contents

What is the pneumococcal polysaccharide serotype 2 vaccine?

The pneumococcal polysaccharide serotype 2 vaccine is a component of certain pneumococcal vaccines that helps protect against infections caused by the serotype 2 strain of Streptococcus pneumoniae bacteria.[1] This serotype is one of many pneumococcal strains that can cause serious illnesses like pneumonia, meningitis, and bloodstream infections.

Pneumococcal vaccines containing this serotype are designed to stimulate the immune system to produce antibodies against the outer coating (polysaccharide) of the serotype 2 pneumococcus. This prepares the body to fight off infections from this particular strain.

How does it work?

The vaccine works by introducing a small amount of the outer sugar coating (polysaccharide) from the serotype 2 pneumococcus into the body. This polysaccharide is linked to a protein carrier, which helps enhance the immune response. When the immune system encounters these vaccine components, it produces antibodies specifically targeted against the serotype 2 pneumococcal strain.[2]

If a person is later exposed to serotype 2 pneumococcal bacteria, their immune system can quickly recognize the polysaccharide coating and mount a rapid defense to prevent infection. This process, known as opsonophagocytic activity (OPA), allows immune cells to more effectively identify and destroy the bacteria.

Who should get this vaccine?

Pneumococcal vaccines containing serotype 2 are recommended for certain groups who are at increased risk for pneumococcal disease, including:

  • Adults 65 years and older
  • People with chronic health conditions like diabetes, heart disease, lung disease, or kidney disease
  • Those with weakened immune systems
  • Children and adults with certain rare conditions that increase pneumococcal risk

The specific recommendations may vary depending on age, health status, and previous pneumococcal vaccination history. Your doctor can advise if a pneumococcal vaccine containing serotype 2 is appropriate for you.[3]

How is it administered?

Pneumococcal vaccines are typically given as an injection into the muscle (intramuscular) of the upper arm or thigh. For most adults, a single dose is recommended. Some people may need additional doses based on their age, health conditions, and previous vaccination status.

The serotype 2 component is usually combined with multiple other pneumococcal serotypes in a single vaccine. Common pneumococcal vaccines that may include serotype 2 are:

  • 23-valent pneumococcal polysaccharide vaccine (PPSV23)
  • 20-valent pneumococcal conjugate vaccine (PCV20)

Your healthcare provider will determine the appropriate vaccine and schedule for your individual situation.[4]

Safety and side effects

Pneumococcal vaccines containing serotype 2 have been shown to be generally safe and well-tolerated. As with any vaccine, some people may experience mild side effects, which typically resolve within a few days. Common side effects can include:

  • Pain, redness, or swelling at the injection site
  • Fatigue
  • Headache
  • Muscle or joint pain
  • Low-grade fever

Serious allergic reactions are rare but can occur. Seek immediate medical attention if you experience symptoms of a severe allergic reaction after vaccination.[5]

Effectiveness

Studies have shown that pneumococcal vaccines containing serotype 2 can effectively stimulate the immune system to produce protective antibodies against this strain. The opsonophagocytic activity (OPA) and immunoglobulin G (IgG) levels, which are measures of the immune response, typically increase significantly after vaccination.[6]

However, it’s important to note that no vaccine is 100% effective. The pneumococcal serotype 2 vaccine helps reduce the risk of infection from this specific strain, but it does not protect against all types of pneumococcal bacteria or other causes of pneumonia.

Ongoing research

Researchers continue to study pneumococcal vaccines to improve their effectiveness and expand protection against various strains. Some current areas of investigation include:

  • Developing new conjugate vaccines that cover more pneumococcal serotypes
  • Studying the long-term effectiveness and potential need for booster doses
  • Evaluating the impact of pneumococcal vaccination on reducing antibiotic resistance
  • Investigating the use of these vaccines in different populations and age groups

Ongoing clinical trials are assessing the safety, tolerability, and immune responses to newer pneumococcal vaccine formulations that may include serotype 2 along with other strains.[7]

Aspect Details
Vaccine Types Pneumococcal polysaccharide vaccines, often including serotype 2 among multiple serotypes
Study Populations Healthy adults, children, individuals at increased risk of pneumococcal disease
Primary Objectives Evaluate safety, tolerability, and immunogenicity of pneumococcal vaccines
Key Measurements Opsonophagocytic activity (OPA), Immunoglobulin G (IgG) levels, adverse events
Safety Monitoring Injection site reactions, systemic reactions, serious adverse events
Immune Response Assessment Antibody levels, geometric mean titers, fold-rise in antibody levels
Trial Durations Vary, but often include follow-up periods of several weeks to months

FAQ

  • What is the main purpose of these clinical trials? The main purpose is to evaluate the safety, tolerability, and immune responses generated by pneumococcal vaccines containing serotype 2, often in combination with other serotypes. The trials aim to assess how well the vaccines protect against pneumococcal infections.
  • Who are the typical participants in these trials? Participants vary across trials but generally include healthy adults, children, and individuals at increased risk of pneumococcal disease due to conditions like diabetes, chronic liver disease, or chronic lung disease.
  • How is the immune response measured in these trials? The immune response is typically measured through blood tests that look at antibody levels, specifically opsonophagocytic activity (OPA) and immunoglobulin G (IgG) levels. These tests help determine how well the vaccine stimulates the immune system to fight pneumococcal bacteria.
  • What are some common side effects monitored in these trials? Common side effects monitored include injection site reactions (like pain, redness, or swelling), systemic reactions (such as fever, fatigue, or headache), and any serious adverse events that may occur after vaccination.
  • How long do these clinical trials typically last? The duration varies, but many trials involve follow-up periods of several weeks to months after vaccination to assess both short-term and longer-term immune responses and safety outcomes.

Ongoing Clinical Trials on Pneumococcal Polysaccharide Serotype 2

  • Study of pneumococcal vaccines in healthy young adults, older adults and people with HIV infection

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Effectiveness of Pneumococcal Vaccines PCV13 and PPV23 in Adults with Acute Leukemia or Lymphoma Undergoing Chemotherapy

    Recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study on Long-Term Kidney Transplant Outcomes in Low-Risk Patients Using Tacrolimus Alone or with Mycophenolate Mofetil

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Safety and Immune Response of V116 Vaccine for Pneumococcal Disease in Adults Aged 50 and Older

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Germany Spain

  • Study on the Best Time for Influenza Vaccine Administration in Adults Aged 60-85 Using Influenza Vaccine and Drug Combination

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Croatia Czechia Denmark +15

  • Study on the Safety and Immune Response of V116 Vaccine in Children and Adolescents at Higher Risk for Pneumococcal Disease

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Finland France Poland Spain Sweden

  • Study on Venetoclax and Dexamethasone for Patients with Relapsed and Refractory Multiple Myeloma with Translocation (11;14)

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Denmark

  • Study on Long-term Safety and Efficacy of Pegcetacoplan for Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Italy +2

Glossary

  • Pneumococcal polysaccharide: A component of the pneumococcal bacteria's outer coating used in vaccines to stimulate an immune response against specific serotypes of the bacteria.
  • Serotype: A distinct variation within a species of bacteria, in this case referring to different strains of pneumococcal bacteria.
  • Opsonophagocytic activity (OPA): A measure of the ability of antibodies to help immune cells engulf and destroy bacteria, used to assess vaccine effectiveness.
  • Immunoglobulin G (IgG): A type of antibody that plays a crucial role in the body's immune response against pathogens like pneumococcal bacteria.
  • Geometric mean titer (GMT): A way of averaging antibody levels in a group of people, used to compare immune responses between different vaccines or groups.
  • Conjugate vaccine: A type of vaccine that joins a weak antigen to a strong antigen to enhance the immune response, often used in pneumococcal vaccines.
  • Adverse event (AE): Any unfavorable medical occurrence in a clinical trial participant, which may or may not be caused by the study treatment.
  • Immunogenicity: The ability of a substance, such as a vaccine, to provoke an immune response in the body.

References

  1. http://clinicaltrials.eu/trial/2023-506236-32-00
  2. http://clinicaltrials.eu/trial/2023-505154-18-00
  3. http://clinicaltrials.eu/trial/2022-502791-22-01
  4. http://clinicaltrials.eu/trial/2023-504625-39-00
  5. http://clinicaltrials.eu/trial/2022-501519-15-00
  6. http://clinicaltrials.eu/trial/2022-503144-40-00
  7. http://clinicaltrials.eu/trial/2022-501988-40-00